GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (MEX:BCRX) » Definitions » Price-to-Free-Cash-Flow

BioCryst Pharmaceuticals (MEX:BCRX) Price-to-Free-Cash-Flow : N/A (As of May. 27, 2025)


View and export this data going back to 2019. Start your Free Trial

What is BioCryst Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2025-05-27), BioCryst Pharmaceuticals's share price is MXN197.50. BioCryst Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-2.58. Hence, BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

MEX:BCRX's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.875
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

BioCryst Pharmaceuticals's Free Cash Flow per Share for the three months ended in Mar. 2025 was MXN-2.63. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was MXN-2.58.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 31.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.80% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 0.10% per year.

During the past 13 years, BioCryst Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 31.70% per year. The lowest was -53.30% per year. And the median was 3.45% per year.


BioCryst Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Price-to-Free-Cash-Flow Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCryst Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow falls into.


;
;

BioCryst Pharmaceuticals Price-to-Free-Cash-Flow Calculation

BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=197.50/-2.577
=N/A

BioCryst Pharmaceuticals's Share Price of today is MXN197.50.
BioCryst Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-2.58.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

BioCryst Pharmaceuticals  (MEX:BCRX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


BioCryst Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.